Gabriel André Pedral Diniz Leite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabriel André Pedral Diniz Leite has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Guilherme Grossi Lopes Cançado
Hospital das Clínicas da Universidade Federal de Minas Gerais Belo Horizonte Brazil
5 shared publications - Bernardo de Faria Moraes
Universidade Federal de Minas Gerais Belo Horizonte Brazil
3 shared publications - Igor Boechat Silveira
Universidade Federal de Juiz de Fora Juiz de Fora Brazil
3 shared publications - Leonardo Corrêa Süffert
Pontifícia Universidade Católica do Rio Grande do Sul Porto Alegre Brazil
3 shared publications Luis Pedro Possapp Beis
Pontifícia Universidade Católica do Rio Grande do Sul Porto Alegre Brazil
3 shared publicationsMaria Luisa Motta Fonseca
Hospital das Clínicas Universidade Federal de Minas Gerais Belo Horizonte Brazil
3 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (10) , 1348-1361
Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974
- 24 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (10) , 1348-1361
Open AccessMeta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974
- 24 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1060-1062
Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
- 24 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1060-1062
Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
- 16 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1065-1067
Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis—Authors' Reply
- 16 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1065-1067
Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis—Authors' Reply
- Top Cited PapersOpen Access
- 10 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (6) , 778-794
Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
Background: The role of statins in cirrhosis remains controversial. Historically restricted due to safety concerns, emerging evidence highlights potential pleiotropic benefits, though effects on mortality and decompensation remain uncertain. Aims: To evaluate the effects of statin therapy on all‐cause mortality, hepatic decompensation, hepatic venous pressure gradient (HVPG), and hepatocellular carcinoma (HCC) in cirrhosis. Methods: We systematically searched major databases until July 2025 for randomised controlled trials (RCTs) and observational studies comparing statin therapy versus non‐use in cirrhosis. Random‐effects meta‐analyses were performed. Results: The meta‐analysis included 25 studies (9 RCTs, 16 observational) with 81,992 patients. Statins reduced all‐cause mortality in the overall analysis (unadjusted odds ratio 0.59; 95% CI: 0.48–0.71) and in RCTs (odds ratio 0.45; 95% CI 0.25–0.82), supported by a significant HVPG reduction. Conversely, statins reduced hepatic decompensation in the overall analysis (unadjusted odds ratio 0.56; 95% CI: 0.47–0.66) but not in RCTs (odds ratio 0.75; 95% CI: 0.52–1.09). Observational data indicated a protective association for HCC (adjusted hazard ratio 0.61; 95% CI: 0.46–0.82), and no RCT reported this outcome. Conclusions: Statin therapy is associated with improved survival in cirrhosis, supported mechanistically by reductions in portal pressure. Observational evidence suggests benefits for decompensation and HCC, though these remain uncertain due to residual confounding. Large‐scale, long‐term RCTs are needed to clarify the role of statins as disease‐modifying therapy in cirrhosis.
- 10 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (6) , 778-794
Top Cited PapersOpen AccessStatin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
Background: The role of statins in cirrhosis remains controversial. Historically restricted due to safety concerns, emerging evidence highlights potential pleiotropic benefits, though effects on mortality and decompensation remain uncertain. Aims: To evaluate the effects of statin therapy on all‐cause mortality, hepatic decompensation, hepatic venous pressure gradient (HVPG), and hepatocellular carcinoma (HCC) in cirrhosis. Methods: We systematically searched major databases until July 2025 for randomised controlled trials (RCTs) and observational studies comparing statin therapy versus non‐use in cirrhosis. Random‐effects meta‐analyses were performed. Results: The meta‐analysis included 25 studies (9 RCTs, 16 observational) with 81,992 patients. Statins reduced all‐cause mortality in the overall analysis (unadjusted odds ratio 0.59; 95% CI: 0.48–0.71) and in RCTs (odds ratio 0.45; 95% CI 0.25–0.82), supported by a significant HVPG reduction. Conversely, statins reduced hepatic decompensation in the overall analysis (unadjusted odds ratio 0.56; 95% CI: 0.47–0.66) but not in RCTs (odds ratio 0.75; 95% CI: 0.52–1.09). Observational data indicated a protective association for HCC (adjusted hazard ratio 0.61; 95% CI: 0.46–0.82), and no RCT reported this outcome. Conclusions: Statin therapy is associated with improved survival in cirrhosis, supported mechanistically by reductions in portal pressure. Observational evidence suggests benefits for decompensation and HCC, though these remain uncertain due to residual confounding. Large‐scale, long‐term RCTs are needed to clarify the role of statins as disease‐modifying therapy in cirrhosis.
- 21 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1851-1865
Re-Evaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-Analysis
INTRODUCTION: The benefit of proton pump inhibitors (PPIs) in improving outcomes after endoscopic band ligation (EBL) of esophageal varices in cirrhosis remains uncertain. We aimed to evaluate whether PPI use reduces bleeding and mortality after EBL compared with nonuse. METHODS: Major databases were systematically searched until January 2025. Randomized clinical trials (RCTs) and observational studies comparing PPI use vs nonuse after EBL of esophageal varices in patients with cirrhosis were included. Random-effects meta-analyses were conducted using restricted maximum likelihood estimation. Risk ratios (RR), odds ratios (ORs), or standardized mean differences with 95% confidence intervals (CIs) were calculated for outcomes. RESULTS: Eleven studies (4 RCTs and 7 observational) comprising 7,459 patients with cirrhosis undergoing EBL were included. In pooled unadjusted analyses, PPI use was associated with reduced post-EBL bleeding (OR 0.76; 95% CI 0.62–0.92; I 2 = 29.6%) and all-cause mortality (OR 0.48; 95% CI 0.24–0.97; I 2 = 0.0%). More rigorous analyses showed no benefit: adjusted observational data for post-EBL bleeding and RCT data for post-EBL bleeding and all-cause mortality were not significant ( P > 0.05). Similarly, for the mechanistic outcome of post-EBL ulcer bleeding, RCT data showed no statistically significant effect (RR 0.54; 95% CI 0.25–1.16; I 2 = 0.0%). Trial sequential analysis confirmed the cumulative RCT evidence for bleeding is underpowered. DISCUSSION: Current evidence is insufficient to support routine PPI use after EBL. RCT data remain underpowered and inconclusive, emphasizing the need for adequately powered trials.
- 21 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1851-1865
Re-Evaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients: A Systematic Review and Meta-Analysis
INTRODUCTION: The benefit of proton pump inhibitors (PPIs) in improving outcomes after endoscopic band ligation (EBL) of esophageal varices in cirrhosis remains uncertain. We aimed to evaluate whether PPI use reduces bleeding and mortality after EBL compared with nonuse. METHODS: Major databases were systematically searched until January 2025. Randomized clinical trials (RCTs) and observational studies comparing PPI use vs nonuse after EBL of esophageal varices in patients with cirrhosis were included. Random-effects meta-analyses were conducted using restricted maximum likelihood estimation. Risk ratios (RR), odds ratios (ORs), or standardized mean differences with 95% confidence intervals (CIs) were calculated for outcomes. RESULTS: Eleven studies (4 RCTs and 7 observational) comprising 7,459 patients with cirrhosis undergoing EBL were included. In pooled unadjusted analyses, PPI use was associated with reduced post-EBL bleeding (OR 0.76; 95% CI 0.62–0.92; I 2 = 29.6%) and all-cause mortality (OR 0.48; 95% CI 0.24–0.97; I 2 = 0.0%). More rigorous analyses showed no benefit: adjusted observational data for post-EBL bleeding and RCT data for post-EBL bleeding and all-cause mortality were not significant ( P > 0.05). Similarly, for the mechanistic outcome of post-EBL ulcer bleeding, RCT data showed no statistically significant effect (RR 0.54; 95% CI 0.25–1.16; I 2 = 0.0%). Trial sequential analysis confirmed the cumulative RCT evidence for bleeding is underpowered. DISCUSSION: Current evidence is insufficient to support routine PPI use after EBL. RCT data remain underpowered and inconclusive, emphasizing the need for adequately powered trials.